Seriously though, this kind of makes sense doesnt it
J Pharm Res
The TRAVERSE trial (2023, 5,204 men) showed no increased cardiovascular risk
10.1016/j.redox.2025.103660 59 KanzokS
In that sense, while still representing a challenging goal to be achieved, the identification of specific prognostic biomarkers and also those for the evaluation of therapeutic efficacy in ALS will have a fundamental role in designing and monitoring new treatment strategies in the complex scenario of the neurodegenerative process
When intra-portal insulin levels are increased (e.g., obesity, Cushings syndrome, or due to treatment with glucocorticoids and glucagon-like peptide 1 receptor agonists) or decreased (e.g., malnutrition, anorexia nervosa and type 1 diabetes mellitus), these changes secondarily alter hepatic GH sensitivity resulting in a secondary association with discordant GH and IGF-I levels (e.g., high GH/low IGF-I levels or low GH/high IGF-I levels, respectively)